EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response

Haoran Zhu, Wanrong Zhang, Qingguo Guo, Ruoyue Fan, Guangzuo Luo iD, Ying Liu

Journal for ImmunoTherapy of Cancer · 2024-11 · 12 (11) · e009901

DOI: 10.1136/jitc-2024-009901 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 29.11.2024. Verfasst von Haoran Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China. Hauptthemen laut MEDLINE: B7 Antigens, Oncolytic Viruses, T-Lymphocytes. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bispecific T-cell engagers (BiTEs) are recombinant bispecific proteins designed to stimulate polyclonal T-cell immunity. In recent years, B7H3, a pan-cancer antigen, has been considered a promising target for future immunotherapy. However, the B7H3-targeting BiTE faces the challenge of systemic toxicity. Oncolytic viruses (OVs) represent a new class of cancer immunotherapeutics and serve as an appropriate platform for locoregional delivery of therapeutic genes. In this study, we designed an oncolytic adenovirus (OAd) encoding BiTE targeting human B7H3. We hypothesized that OVs encoding B7H3 BiTE deliver this molecule persistently to the tumor site while mediating polyclonal T-cell activation and redirecting it to tumor cells.

Methods

B7H3-targeting BiTE was constructed by linking a single-chain variable fragment (scFv) that recognizes human B7H3 to an scFv that recognizes human CD3. B7H3 BiTE was inserted into OAd to construct OAd-B7H3-BiTE. The function of the OV-delivered B7H3 BiTE was detected via co-culturing B7H3 + target cells and peripheral blood mononuclear cells. A humanized immune system mouse model was used to evaluate the therapeutic effects in vivo.

Results

B7H3 is highly expressed in a high proportion of human malignancies. OV-delivered BiTEs bind to T cells and target cells. We observed a series of phenomena reflecting T-cell activation induced by OAd-B7H3-BiTE, including cell clustering, cell size, activation markers, cytokine secretion, and proliferation. Furthermore, T-cell activation was mirrored by the corresponding cytotoxicity against B7H3 + tumor cells. In vivo, B7H3 BiTE was persistently expressed in tumors and enhanced the antitumor T-cell immune response.

Conclusions

Using an OV for the local expression of B7H3 BiTE maximizes the local concentration of BiTE while reducing systemic exposure. OV also provides a relatively “hot” T-cell immune environment for the function of BiTE. Because of its capacity to activate polyclonal T cells, BiTE has the potential to redirect virus-specific T cells to tumors. Our study provides new opportunities for the exploitation of B7H3-BiTE-armed OVs as therapeutic agents for the treatment of B7H3-positive malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7 AntigensOncolytic VirusesT-LymphocytesAnimalsHumansMiceOncolytic VirotherapyAntibodies, BispecificNeoplasmsCell Line, TumorFemaleImmunotherapyLymphocyte Activation

Stichwörter der Autor:innen

Bispecific T cell engager - BiTEImmunotherapyOncolytic virusT cell

Substanzen

B7 AntigensCD276 protein, humanAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China.
  • Bionce Biotechnology, Ltd, Nanjing, China.
  • Bionce Biotechnology, Ltd, Nanjing, China gzluo@cmu.edu.cn liuying@cmu.edu.cn.
  • Institute of Health Science, China Medical University, Shenyang, China.
  • Department of Biochemistry and Molecular Biology, China Medical University, Shenyang, China gzluo@cmu.edu.cn liuying@cmu.edu.cn.

ORCID-Profile: Guangzuo Luo

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, H., Zhang, W., Guo, Q., Fan, R., Luo, G., & Liu, Y. (2024). Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response. Journal for ImmunoTherapy of Cancer, 12(11), e009901. https://doi.org/10.1136/jitc-2024-009901

Vancouver

Zhu H, Zhang W, Guo Q, Fan R, Luo G, Liu Y. Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response. Journal for ImmunoTherapy of Cancer. 2024;12(11):e009901. doi:10.1136/jitc-2024-009901

BibTeX
@article{Zhu2024,
  author = {Zhu, Haoran and Zhang, Wanrong and Guo, Qingguo and Fan, Ruoyue and Luo, Guangzuo and Liu, Ying},
  title = {Engineered oncolytic virus expressing B7H3-targeting BiTE enhances antitumor T-cell immune response},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  volume = {12},
  number = {11},
  pages = {e009901},
  doi = {10.1136/jitc-2024-009901}
}
Kostenlos starten →